BelVitunipharm preparing to launch production of COVID vaccine adapted to Belarusians’ genotype

The working meeting at BelVitunipharm JSC discussed the commissioning of a pilot plant for the production of a vaccine against COVID-19 and import substitution of other vaccines that are used in the healthcare of our country, but are imported from abroad

BelVitunipharm JSC is a high-tech enterprise for the production of veterinary drugs, which occupies one of the leading positions in the biological industry of Belarus and the CIS. Soon the first pilot production of anti-COVID vaccine will open here.

According to academician Vladimir Gusakov, the Chairman of the Presidium of the National Academy of Sciences of Belarus, the Academy of Sciences, together with the Healthcare Ministry, has created a prototype of a vaccine against coronavirus infection, which has passed laboratory and preclinical tests, confirming the effectiveness of the drug. With the development of an experimental batch, clinical trials on volunteers will also be carried out. The academician claims that the Belarusian vaccine against coronavirus infection is equal in its characteristics to foreign analogues but is adapted to the genotype of the Belarusian people.

“We have already come close to the launch of pilot production, which should take place at the end of the month. Here we will be able to produce not only a vaccine for the prevention of COVID infection, but also, if necessary, a whole range of other necessary vaccines and drugs that are used in domestic healthcare,” said Aleksandr Subbotin, the Chairman of the Vitebsk Regional Executive Committee.